Core Insights - Acushnet reported quarterly earnings of $0.81 per share, missing the Zacks Consensus Estimate of $0.85 per share, and down from $0.89 per share a year ago, representing an earnings surprise of -4.71% [1] - The company posted revenues of $657.66 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 3.78% and up from $620.5 million year-over-year [2] - Acushnet shares have increased approximately 5.9% year-to-date, compared to a 15.1% gain in the S&P 500 [3] Earnings Performance - Over the last four quarters, Acushnet has surpassed consensus EPS estimates two times [2] - The company had a previous earnings expectation of $1.33 per share, but reported $1.25, resulting in a surprise of -6.02% [1] Future Outlook - The company's earnings outlook will be crucial for stock performance, with current consensus EPS estimates at -$0.23 for the upcoming quarter and $3.47 for the current fiscal year [7] - The Zacks Rank for Acushnet is currently 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6] Industry Context - The Leisure and Recreation Products industry, to which Acushnet belongs, is currently ranked in the top 27% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Acushnet's stock performance [5]

Core Insights - Hackett Group reported quarterly earnings of $0.37 per share, matching the Zacks Consensus Estimate, but down from $0.43 per share a year ago [1] - The company posted revenues of $72.17 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 2.02% and down from $77.95 million year-over-year [2] - Hackett Group shares have declined approximately 41.4% year-to-date, contrasting with the S&P 500's gain of 16.5% [3] Earnings Performance - The company has surpassed consensus EPS estimates two times over the last four quarters [1] - Hackett Group has topped consensus revenue estimates three times in the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is $0.38, with expected revenues of $75.1 million, and for the current fiscal year, the estimate is $1.52 on revenues of $302.58 million [7] Market Outlook - The stock's immediate price movement will largely depend on management's commentary during the earnings call [3] - The estimate revisions trend for Hackett Group was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] - The Consulting Services industry is currently ranked in the top 26% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Core Insights - Agilon Health (AGL) reported a quarterly loss of $0.27 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.18, marking an earnings surprise of -50.00% [1] - The company generated revenues of $1.44 billion for the quarter ended September 2025, slightly surpassing the Zacks Consensus Estimate by 0.57%, but down from $1.45 billion a year ago [2] - Agilon shares have declined approximately 57.4% year-to-date, contrasting with the S&P 500's gain of 16.5% [3] Financial Performance - Over the last four quarters, Agilon has exceeded consensus EPS estimates only once [2] - The current consensus EPS estimate for the upcoming quarter is -$0.19 on revenues of $1.47 billion, and for the current fiscal year, it is -$0.56 on revenues of $5.82 billion [7] Market Outlook - The company's Zacks Rank is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] - The Medical Services industry, to which Agilon belongs, is ranked in the bottom 43% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Core Insights - Par Petroleum (PARR) reported quarterly earnings of $5.95 per share, significantly exceeding the Zacks Consensus Estimate of $1.98 per share, and compared to a loss of $0.1 per share a year ago, representing an earnings surprise of +200.51% [1] - The company posted revenues of $2.01 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 5.40%, although this is a decrease from year-ago revenues of $2.14 billion [2] - Par Petroleum shares have increased by approximately 151.4% since the beginning of the year, outperforming the S&P 500's gain of 16.5% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.43 on revenues of $1.81 billion, and for the current fiscal year, it is $3.89 on revenues of $7.36 billion [7] - The estimate revisions trend for Par Petroleum was favorable ahead of the earnings release, resulting in a Zacks Rank 1 (Strong Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Oil and Gas - Refining and Marketing industry is currently ranked in the top 18% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8] - Another company in the same industry, Delek US Holdings (DK), is expected to report quarterly earnings of $0.14 per share, reflecting a year-over-year change of +109.7%, with a consensus EPS estimate revised 36.9% higher over the last 30 days [9]

Core Insights - Latham Group reported quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.10 per share, representing a -20.00% earnings surprise [1] - The company posted revenues of $161.9 million for the quarter ended September 2025, which was 1.28% below the Zacks Consensus Estimate, compared to $150.5 million in the same quarter last year [2] Earnings Performance - Over the last four quarters, Latham Group has surpassed consensus EPS estimates two times [2] - The company had a previous quarter earnings expectation of $0.13 per share but reported $0.14, resulting in a +7.69% surprise [1] Stock Performance - Latham Group shares have increased approximately 4.5% since the beginning of the year, while the S&P 500 has gained 16.5% [3] Future Outlook - The company's earnings outlook will be crucial for investors, including current consensus earnings expectations for upcoming quarters [4] - The current consensus EPS estimate for the next quarter is -$0.09 on revenues of $93 million, and $0.10 on revenues of $541 million for the current fiscal year [7] Industry Context - The Building Products - Miscellaneous industry, to which Latham Group belongs, is currently ranked in the bottom 39% of over 250 Zacks industries, indicating potential challenges [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Latham Group's stock performance [5][6]

Group 1 - CeriBell, Inc. reported a quarterly loss of $0.37 per share, better than the Zacks Consensus Estimate of a loss of $0.43, and an improvement from a loss of $1.85 per share a year ago, resulting in an earnings surprise of +13.95% [1] - The company posted revenues of $22.59 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 3.65%, and showing an increase from $17.19 million in the same quarter last year [2] - CeriBell, Inc. has surpassed consensus EPS estimates three times over the last four quarters and has topped consensus revenue estimates four times in the same period [2] Group 2 - The stock has underperformed, losing about 56.2% since the beginning of the year, while the S&P 500 has gained 16.5% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.42 on revenues of $23.33 million, and for the current fiscal year, it is -$1.55 on revenues of $86.82 million [7] - The Zacks Industry Rank for Medical - Products is in the bottom 41% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Core Insights - CryoPort, Inc. reported a quarterly loss of $0.18 per share, better than the Zacks Consensus Estimate of a loss of $0.23, representing an earnings surprise of +21.74% [1] - The company posted revenues of $44.23 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 8.32%, although this is a decline from $56.66 million in the same quarter last year [2] - CryoPort shares have increased by approximately 16.2% year-to-date, slightly underperforming the S&P 500's gain of 16.5% [3] Earnings Outlook - The earnings outlook for CryoPort is mixed, with the current consensus EPS estimate for the upcoming quarter at -$0.20 on revenues of $43.17 million, and -$0.85 on revenues of $170.5 million for the current fiscal year [7] - The company's Zacks Rank is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical Services industry, to which CryoPort belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, suggesting potential challenges ahead [8] - The Oncology Institute, Inc., another company in the same industry, is expected to report a quarterly loss of $0.12 per share, with revenues projected to be $122.25 million, reflecting a year-over-year increase of 22.4% [9][10]

Core Insights - Clearway Energy (CWEN) reported quarterly earnings of $2 per share, significantly exceeding the Zacks Consensus Estimate of $0.32 per share, and up from $0.31 per share a year ago [1][2] - The earnings surprise of +525.00% marks a notable improvement compared to the previous quarter, where the company reported earnings of $0.28 per share against an expectation of $0.67, resulting in a surprise of -58.21% [2] - The company generated revenues of $429 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.60%, although this is a decrease from $486 million in the same quarter last year [3] Financial Performance - Clearway Energy has surpassed consensus EPS estimates two times over the last four quarters [2] - The company has topped consensus revenue estimates just once in the last four quarters [3] - The current consensus EPS estimate for the upcoming quarter is -$0.16 on revenues of $323.82 million, while for the current fiscal year, it is $0.61 on revenues of $1.44 billion [8] Market Position - Clearway Energy shares have increased approximately 25% since the beginning of the year, outperforming the S&P 500's gain of 16.5% [4] - The Zacks Rank for Clearway Energy is currently 3 (Hold), indicating expected performance in line with the market in the near future [7] - The Alternative Energy - Other industry, to which Clearway Energy belongs, is currently ranked in the bottom 33% of over 250 Zacks industries, suggesting potential challenges ahead [9] Future Outlook - The sustainability of the stock's price movement will largely depend on management's commentary during the earnings call and future earnings expectations [4][5] - The trend of estimate revisions for Clearway Energy was mixed prior to the earnings release, and changes in estimates are anticipated following the recent results [7] - Investors are encouraged to monitor how estimates for the upcoming quarters and the current fiscal year evolve in the coming days [8]

Core Insights - Day One Biopharmaceuticals reported a quarterly loss of $0.19 per share, better than the Zacks Consensus Estimate of a loss of $0.28, representing an earnings surprise of +32.14% [1] - The company posted revenues of $39.8 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 5.75%, but down from $93.76 million year-over-year [2] - The stock has underperformed, losing about 42.3% since the beginning of the year compared to the S&P 500's gain of 16.5% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.26 on revenues of $42.15 million, and for the current fiscal year, it is -$1.19 on revenues of $144.36 million [7] - The estimate revisions trend for Day One Biopharmaceuticals was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Day One Biopharmaceuticals belongs, is currently in the top 39% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Insights - Tango Therapeutics, Inc. reported quarterly earnings of $0.13 per share, significantly exceeding the Zacks Consensus Estimate of $0.01 per share, and showing a substantial improvement from a loss of $0.27 per share a year ago, resulting in an earnings surprise of +1,200.00% [1] - The company generated revenues of $53.81 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 23.20%, compared to revenues of $11.61 million in the same quarter last year [2] - Tango Therapeutics shares have increased approximately 159.2% year-to-date, outperforming the S&P 500's gain of 16.5% [3] Earnings Outlook - The future performance of Tango Therapeutics' stock will largely depend on management's commentary during the earnings call and the company's earnings outlook, which includes current consensus earnings expectations for upcoming quarters [4][6] - The current consensus EPS estimate for the next quarter is -$0.36 on revenues of $4.84 million, and for the current fiscal year, it is -$1.04 on revenues of $52.9 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Tango Therapeutics belongs, is currently ranked in the top 39% of over 250 Zacks industries, indicating a favorable outlook for stocks within this sector [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked using tools like the Zacks Rank [5]